- Home
- FOR vs AKBA Comparison
FOR vs AKBA Comparison
Compare FOR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- AKBA
- Stock Information
- Founded
- FOR 2005
- AKBA 2007
- Country
- FOR United States
- AKBA United States
- Employees
- FOR N/A
- AKBA N/A
- Industry
- FOR Real Estate
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- AKBA Health Care
- Exchange
- FOR Nasdaq
- AKBA Nasdaq
- Market Cap
- FOR 1.0B
- AKBA 958.6M
- IPO Year
- FOR 2007
- AKBA 2014
- Fundamental
- Price
- FOR $19.49
- AKBA $3.68
- Analyst Decision
- FOR Strong Buy
- AKBA Strong Buy
- Analyst Count
- FOR 3
- AKBA 5
- Target Price
- FOR $30.33
- AKBA $6.90
- AVG Volume (30 Days)
- FOR 147.8K
- AKBA 6.1M
- Earning Date
- FOR 07-22-2025
- AKBA 08-07-2025
- Dividend Yield
- FOR N/A
- AKBA N/A
- EPS Growth
- FOR N/A
- AKBA N/A
- EPS
- FOR 3.29
- AKBA N/A
- Revenue
- FOR $1,471,000,000.00
- AKBA $184,909,000.00
- Revenue This Year
- FOR $3.95
- AKBA $26.88
- Revenue Next Year
- FOR $8.86
- AKBA $44.34
- P/E Ratio
- FOR $5.94
- AKBA N/A
- Revenue Growth
- FOR N/A
- AKBA N/A
- 52 Week Low
- FOR $18.00
- AKBA $0.80
- 52 Week High
- FOR $37.21
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- FOR 46.69
- AKBA 64.49
- Support Level
- FOR $19.32
- AKBA $3.46
- Resistance Level
- FOR $21.23
- AKBA $3.98
- Average True Range (ATR)
- FOR 0.60
- AKBA 0.25
- MACD
- FOR -0.03
- AKBA -0.04
- Stochastic Oscillator
- FOR 30.40
- AKBA 64.20
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.